Xenon Pharmaceuticals Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Xenon Pharmaceuticals stock.
View analyst ratings for Xenon Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Xenon Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Xenon Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Xenon Pharmaceuticals saw a decline in short interest during the month of May. As of May 28th, there was short interest totaling 657,400 shares, a decline of 13.5% from the May 13th total of 759,600 shares. Based on an average trading volume of 154,700 shares, the days-to-cover ratio is presently 4.2 days. Currently, 1.8% of the company's stock are short sold.
View Xenon Pharmaceuticals' Short Interest.

Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Xenon Pharmaceuticals.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) posted its quarterly earnings data on Tuesday, May, 11th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.45) by $0.03. The biopharmaceutical company earned $4.36 million during the quarter, compared to analysts' expectations of $3.70 million. Xenon Pharmaceuticals had a negative trailing twelve-month return on equity of 18.84% and a negative net margin of 126.05%.
View Xenon Pharmaceuticals' earnings history.

Xenon Pharmaceuticals' stock was trading at $12.71 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, XENE stock has increased by 46.3% and is now trading at $18.60.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued 1 year price targets for Xenon Pharmaceuticals' stock. Their forecasts range from $25.00 to $28.00. On average, they expect Xenon Pharmaceuticals' share price to reach $26.00 in the next year. This suggests a possible upside of 39.8% from the stock's current price.
View analysts' price targets for Xenon Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Xenon Pharmaceuticals include PTC Therapeutics (PTCT), Rocket Pharmaceuticals (RCKT), IGM Biosciences (IGMS), Dicerna Pharmaceuticals (DRNA), Taro Pharmaceutical Industries (TARO), Amicus Therapeutics (FOLD), Cryoport (CYRX), MorphoSys (MOR), Pacira BioSciences (PCRX), Prestige Consumer Healthcare (PBH), Global Blood Therapeutics (GBT), Corcept Therapeutics (CORT), Axsome Therapeutics (AXSM), OPKO Health (OPK) and FibroGen (FGEN).
View all of XENE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI).

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Xenon Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (8.50%), Bank of New York Mellon Corp (2.34%), Ghost Tree Capital LLC (2.08%), Point72 Asset Management L.P. (1.86%), Baker BROS. Advisors LP (1.83%) and Renaissance Technologies LLC (1.69%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends for Xenon Pharmaceuticals.

XENE stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Millennium Management LLC, Granite Point Capital Management L.P., Knott David M, Acadian Asset Management LLC, BlackRock Inc., Bank of Montreal Can, and BVF Inc. IL. Company insiders that have sold Xenon Pharmaceuticals company stock in the last year include Frank A Holler, and Sherrington Robin.
View insider buying and selling activity for Xenon Pharmaceuticals or view top insider-selling stocks.

XENE stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Suvretta Capital Management LLC, Lord Abbett & CO. LLC, Acuta Capital Partners LLC, Point72 Asset Management L.P., Tekla Capital Management LLC, and Citadel Advisors LLC.
View insider buying and selling activity for Xenon Pharmaceuticals or or view top insider-buying stocks.

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XENE stock can currently be purchased for approximately $18.60.

Xenon Pharmaceuticals has a market capitalization of $761.99 million and generates $32.17 million in revenue each year. The biopharmaceutical company earns $-28,840,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

Xenon Pharmaceuticals employs 123 workers across the globe.

The official website for Xenon Pharmaceuticals is www.xenon-pharma.com.

Xenon Pharmaceuticals is headquartered at 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W.

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]